Emmessar Biotech & Nutrition Limited (524768) Fair Value & Analysis
Other · IN · Market cap ₹71.2M
Fair value as of: Jul 4, 2026
From 15 valuation models · updated today
Share price −5.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹19.99 – ₹39.20 · fair‑value band ₹11.12 – ₹14.72 · the ₹24.47 price screens above the ₹11.75 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Emmessar Biotech & Nutrition Limited (524768) currently trades at ₹24.47, while our model-based Fair Value estimate is ₹11.75 — implying the stock looks roughly 52.0% overvalued today. We read business quality at 55/100 (solid quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Emmessar Biotech & Nutrition Limited generated revenue of ₹30.0M at a net margin of 12.8%. Revenue declined 78.3% year over year. The stock trades on a trailing P/E of 19.9. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Emmessar Biotech & Nutrition Limited, a healthcare company, manufactures and markets healthcare and nutritional products in India and internationally. It operates through Healthcare, Fine Chemicals, and Rent on Lease Land segments. The company offers bone care, general health, muscle care, pain relief, sexual health, skin care, and skin cure products. The company was formerly known as Emmessar Chemical Industries Ltd. and changed its name to Emmessar Biotech & Nutrition Limited in April 2000. Emmessar Biotech & Nutrition Limited was founded in 1992 and is headquartered in Mumbai, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Emmessar Biotech & Nutrition Limited reported revenue of ₹3.7M in FY2026 versus ₹3.6M in FY2022, a compound +0.4%/yr. Reported net income was ₹4.4M in FY2026, compounding −2.1%/yr from FY2022.
Is 524768 fairly valued? → Check now
Similar stocks
6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €209.16 | -60% |
| Sony Corporation SON1 | €17.58 | €37.56 | +114% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $28.75 | +71% |
| 533278 533278 | ₹438.60 | ₹720.31 | +64% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹279.60 | -81% |
| 540376 540376 | ₹3,993 | ₹1,806 | -55% |
Explore undervalued stocks
Frequently asked questions
Is Emmessar Biotech & Nutrition Limited (524768) undervalued?
What is the fair value of 524768?
What is the quality score of 524768?
What is the revenue of Emmessar Biotech & Nutrition Limited (524768)?
What is the net profit margin of 524768?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.